Contrast-enhanced MRI in Children 2 Months to <2 Years

Completed · Phase 3

Conditions studied: Magnetic Resonance Imaging

In brief

The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to \< 2 years of age

Key facts

Study ID

NCT00937391

Run by

Bayer

People needed

54

Starts

2010-01-01

Expected to finish

2010-09-01

Last updated by the study team

2015-11-18

Who can join

Age: 0 and older, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 2 months to < 2 years (23 months)
• Participants (male/female) who are scheduled to undergo gadolinium-enhanced MRI
• Able to comply with the study procedures

You may not qualify if…

• Clinical unstable participants (eg, intensive care unit)
• Renal Insufficiency
• Participants undergoing chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Magnevist.

Where it is running

• Study site — San Diego, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Chicago, Illinois, United States
• Study site — Iowa City, Iowa, United States
• Study site — Kansas City, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Akron, Ohio, United States
• Study site — Hershey, Pennsylvania, United States
• Study site — Houston, Texas, United States
• Study site — Dresden, Saxony, Germany
• Study site — Halle, Saxony-Anhalt, Germany
• Study site — Kiel, Schleswig-Holstein, Germany
• Study site — Jena, Thuringia, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.